Cargando…

Shared sorrow, shared costs: cost-effectiveness analysis of the Empowerment group therapy approach to treat affective disorders in refugee populations

BACKGROUND: Refugees and asylum seekers (RAS) in Germany need tailored and resource-oriented mental healthcare interventions. AIMS: To evaluate the cost-effectiveness of group psychotherapy for RAS with moderate depressive symptoms. METHOD: This is a post hoc cost-effectiveness analysis of Empowerme...

Descripción completa

Detalles Bibliográficos
Autores principales: Strupf, Michael, Hoell, Andreas, Bajbouj, Malek, Böge, Kerem, Wiechers, Maren, Karnouk, Carine, Kamp-Becker, Inge, Banaschewski, Tobias, Meyer-Lindenberg, Andreas, Rapp, Michael, Hasan, Alkomiet, Falkai, Peter, Habel, Ute, Heinz, Andreas, Plener, Paul, Kaiser, Franziska, Weigold, Stefanie, Mehran, Nassim, Übleis, Aline, Padberg, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305100/
https://www.ncbi.nlm.nih.gov/pubmed/37345544
http://dx.doi.org/10.1192/bjo.2023.504
Descripción
Sumario:BACKGROUND: Refugees and asylum seekers (RAS) in Germany need tailored and resource-oriented mental healthcare interventions. AIMS: To evaluate the cost-effectiveness of group psychotherapy for RAS with moderate depressive symptoms. METHOD: This is a post hoc cost-effectiveness analysis of Empowerment group psychotherapy that was embedded in a stratified stepped and collaborative care model (SCCM) from the multicentre randomised controlled MEHIRA trial. One hundred and forty-nine participants were randomly assigned to SCCM or treatment as usual (TAU) and underwent Empowerment (i.e. level 3 of the SCCM for adults) or TAU. Effects were measured with the nine-item Patient Health Questionnaire (PHQ-9) and quality adjusted life-years (QALY) post-intervention. Health service and intervention costs were measured. Incremental cost-effectiveness ratios (ICER) were estimated and net monetary benefit (NMB) regressions with 95% confidence intervals were performed. Cost-effectiveness was ascertained for different values of willingness to pay (WTP) using cost-effectiveness acceptability curves for probable scenarios. Trial registration number: NCT03109028 on ClinicalTrials.gov. RESULTS: Health service use costs were significantly lower for Empowerment than TAU after 1 year. Intervention costs were on average €409.6. Empowerment led to a significant change in PHQ-9 scores but not QALY. Bootstrapped mean ICER indicated cost-effectiveness according to PHQ-9 and varied considerably for QALY in the base case. NMB for a unit reduction in PHQ-9 score at WTP of €0 was €354.3 (€978.5 to −€269.9). Results were confirmed for different scenarios and varying WTP thresholds. CONCLUSIONS: The Empowerment intervention was cost-effective in refugees with moderate depressive symptoms regarding the clinical outcome and led to a reduction in direct healthcare consumption. Concerning QALYs, there was a lack of confidence that Empowerment differed from TAU.